Plain-English translation of NCT04292080 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether Dimethyl Fumarate (a medication already used to treat multiple sclerosis) can help slow or stop vision loss in people with geographic atrophy, a serious form of dry macular degeneration. Geographic atrophy causes progressive damage to the light-sensitive cells in the back of the eye, leading to irreversible blindness. This medication works by reducing inflammation and oxidative stress in the eye, which researchers believe are key drivers of the disease.
Currently, there is no cure or proven treatment for geographic atrophy, and millions of people worldwide are losing their vision to this condition. This trial exists because new research suggests that reducing inflammation and oxidative damage might slow or prevent the eye damage that causes vision loss.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to receive the medication, you will take oral pills twice daily for one year (starting with a lower dose for the first week, then a higher dose for 51 weeks). If assigned to the comparison group, you will receive standard care without this medication. All participants will be followed for up to 24 months with regular clinic visits to monitor your eye health, have photographs taken of your retina, and complete vision tests. The study team will watch closely for any side effects and measure whether the medication slows the growth of the damaged areas in your eye.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France